Novel agents have expanded the therapeutic armamentarium for MM, which includes proteasome inhibitors (PIs) such as bortezomib, carfilzomib and ixazomib; immunomodulatory drugs (IMiDs) such as lenalidomide, thalidomide and pomalidomide; monoclonal antibodies such as the anti‐CD38 antibodies daratumumab and isatuximab and the anti‐SLAMF7 (CD319) antibody elotuzumab; and chimeric antigen receptor (CAR) T‐cell therapies [1, 4]. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.